Related Experiment Video

Updated: May 31, 2026

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria
06:38

Screening and Isolation of C-Glycoside-Cleaving Intestinal Bacteria

Published on: February 28, 2025

Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract

Milan Stefek1

  • 1Institute of Experimental Pharmacology & Toxicology, Slovak Academy of Sciences, SK-84104 Bratislava, Slovak Republic.

Interdisciplinary Toxicology
|July 15, 2011
PubMed

Insights

Natural flavonoids show promise in preventing diabetic cataract, a common diabetes complication. These compounds may counteract key cataract-forming mechanisms, offering potential non-surgical treatment options.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic cataract is an early complication of diabetes mellitus.
  • Lens opacity in diabetes results from multifactorial processes including glucose toxicity, oxidative stress, non-enzymatic glycation, and the polyol pathway.
  • There is a need for non-surgical treatments for diabetic cataract.

Purpose of the Study:

  • To review natural flavonoids as potential agents for preventing diabetic cataract.
  • To explore how flavonoids affect multiple pathways involved in eye lens opacification.
  • To consider the bioavailability of flavonoids for the eye lens.

Main Methods:

  • Literature review of scientific evidence on natural flavonoids and diabetic cataract.
  • Analysis of proposed mechanisms by which flavonoids may prevent lens opacity.
  • Consideration of flavonoid bioavailability in the context of eye lens health.

Main Results:

  • Natural flavonoids possess pharmacological actions that may prevent diabetic cataract.
  • Flavonoids can potentially target multiple etiological factors contributing to diabetic cataract.
  • The bioavailability of flavonoids for the eye lens is a crucial factor for their therapeutic efficacy.

Conclusions:

  • Natural flavonoids represent a promising avenue for non-surgical prevention of diabetic cataract.
  • Targeting multiple pathways with flavonoids may offer a comprehensive approach to mitigating diabetic cataract.
  • Further research into flavonoid bioavailability is essential for developing effective therapeutic strategies.
Keywords:
aldose reductase inhibitorsantioxidansdiabetic cataractglycation inhibitorsnatural flavonoidsoxidative stress

More Related Videos

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade09:50

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Published on: August 14, 2019

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.